Novartis Diovan Heart Failure Indication Covers 1.2-2.5 Million Patients
This article was originally published in Pharmaceutical Approvals Monthly
Novartis will be targeting 1.2 mil. to 2.5 mil. patients with the August 14 approval of Diovan for "treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors."
You may also be interested in...
AstraZeneca’s upcoming Atacand sNDA for use in heart failure will likely raise issues about conflicting data on another agent in the same class.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011